11) Publication number:

0 364 819 A3

12

EUROPEAN PATENT APPLICATION

21) Application number: 89118460.8

(9) Int. Cl.5: **C07K** 7/20, A61K 37/02

2 Date of filing: 05.10.89

Priority: 21.10.88 US 260994 07.09.89 US 404667

Date of publication of application: 25.04.90 Bulletin 90/17

Designated Contracting States:
 AT BE CH DE ES FR GB GR IT LI LU NL SE

Date of deferred publication of the search report: 06.03.91 Bulletin 91/10

7) Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND 1430 Tulane Avenue New Orleans, LA 70112(US)

② Inventor: Schally, Andrew V. 5025 Kawanne Avenue Metairie, LA 70002(US) Inventor: Bajuz, Sandor

> H-1016 Budapest(HU) Inventor: Janaky, Tamas 3912 Hessmer Avenue Metairie, LA 70002(US)

Derek ut 16/a

Representative: Dr. Fuchs, Dr. Luderschmidt Dipl.-Phys. Selds, Dr. Mehler Patentanwälte Abraham-Lincoln-Strasse 7 W-6200 Wiesbaden(DE)

LHRH analogs.

(5) The present invention deals with LHRH analogues which contain cytotoxic moleties and have influence on the release of gonadotropins from the pituitary gland of mammals, including humans. The compounds of this invention are represented by the formula:

X-R¹-R²-R³-Ser-R⁵-R⁶(Q)-Leu-Arg-Pro-R¹⁰-NH₂

wherein

R1 is pGlu, Pro, D-Nal(2), or D-Phe(4Cl),

R2 is His or D-Phe(4CI),

R3 is Trp, D-Trp or D-Pal(3),

R5 is Tyr or Arg,

R6 is D-Phe or R6, where R6 is D-Om, D-Lys or D-Phe(NH2),

R10 is Gly or D-Ala,

X is hydrogen, a lower alkanoyl group of 2-5 carbon atoms or carbamyl,

Q is bis-(2-chloroethyl)amino group provided that R⁶ is D-Phe,

where R5 is R5,

Q is a complexed metal-containing acyl group having the formula:

[(Q')(A)] or $[(Q'')(B)_2(A)]$

111

FP O

2

wherein

Q' is $Pt(Y)_2$, where Y is an anion derived from a pharmaceutically acceptable acid, A is a diaminoacyl group having the formula

EP 0 364 819 A3

 $\begin{array}{cccc} \text{CH}_2\text{-}(\text{CH}_2)_m\text{-CH}\text{-}(\text{CH}_2)_n\text{-CO[-NH}\text{-}(\text{CH}_2)_o\text{-CO]}_p\text{-}&\text{IV}\\ & | & | & | & \\ \text{NH}_2 & \text{NH}_2 & & | & \\ \end{array}$

where m is 0 or 1, n and p are 0-10, o is 1-10,

Q'' is a non-platinum-group metal, either a main-group metal such as gallium, germanium, and tin, or a transition metal such as titanium, vanadium, iron, copper, cobalt, gold, nickel, cadmium and zinc,

B is a aralkylidene, heteroaralkylidene, cycloalkylidene or heterocycloalkylidene group containing oxygen anion or carboxylate anion at position 2 or 3, and pharmaceutically acceptable salts thereof and methods of use pertaining these compounds.



EUROPEAN SEARCH REPORT

EP 89 11 8460

ategory		Indication, where appropriate, ant passages		vant talm	CLASSIFICATION OF THE APPLICATION (Int. CI.5)
A	NT. J. PEPT. PROT. RES., vol. 32, no. 1, 1988, pages 6-63; A. RICOUART et al.: "Photosubstitution of cyman-renylalanine as a tool in peptide chemistry" Pages 56-57, column 1 *		1,5-10		C 07 K 7/20 A 61 K 37/43
D,A	CHEMICAL ABSTRACTS, vol. 94, 1981, page 49, abstract no. 11195j, Columbus, Ohio, US; K. CHANNABASAVAIAH et al.: "New potent agonist and antagonist analogs of luteinizing hormone releasing hormone", & PEPT., STRUCT. BIOL. FUNCT:, PROC. AM. PEPT. SYMP., 6TH 1979, 803-6		1-4		
A	J. ENDOCRINOL. INVEST., B.J.A. FURR et al.: "Luteiniz and its analogues: a review of clinical uses" " Page 540, column 2 - page		1-10		
P,X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 86, no. 16, August 1989, pages 6313-6317, Washington, DC, US; S. BAJUSZ et al.: "Highly potent metallopeptide analogues of luteinizing hormonereleasing hormone" * Entire article *		1,5-	10	TECHNICAL FIELDS SEARCHED (Int. Cl.5) C 07 K A 61 K
P,X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCI- ENCES OF THE USA, vol. 86, no. 16, August 1989, pages 6318-6322, Washington, DC, US; S. BAJUSZ et al.: "Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6" * Entire article *		1-4		
					
	The present search report has t	een drawn up for all claims			
	Place of search	Date of completion of search	' 		Examiner
The Hague 28 November 90		GROENENDIJK M.S.M.			
Y: A: 0:	CATEGORY OF CITED DOCL particularly relevant if taken alone particularly relevant if combined wit document of the same catagory technological background non-written disclosure intermediate document	MENTS E: earl the h another D: doc L: doc	filing da ument c ument c	ited in the	ment, but published on, or after the application other reasons

THIS PAGE BLANK (USPTO)